1. Scrip
  2. >>Business

Back To The Drawing Board For Double Bond's Temodex Mission

 
• By Lubna Ahmed

A failed deal has left Double Bond Pharmaceuticals again on the search for a partner in order to take its lead products forward. CEO Igor Lokot shares next steps and partnering plans.

Business Maze_1200

Uppsala, Sweden-based Double Bond Pharmaceutical International AB is once more on the hunt for a partner for its gel formulation of temozolomide, Temodex, for use in brain cancer after a licensing deal with an international company fell through.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.